ATE318322T1 - Virale kernproteine-kationische lipid- nukleinsäure-verabreichungkomplexe - Google Patents

Virale kernproteine-kationische lipid- nukleinsäure-verabreichungkomplexe

Info

Publication number
ATE318322T1
ATE318322T1 AT00981481T AT00981481T ATE318322T1 AT E318322 T1 ATE318322 T1 AT E318322T1 AT 00981481 T AT00981481 T AT 00981481T AT 00981481 T AT00981481 T AT 00981481T AT E318322 T1 ATE318322 T1 AT E318322T1
Authority
AT
Austria
Prior art keywords
cationic lipid
noi
complexes
nucleic acid
core proteins
Prior art date
Application number
AT00981481T
Other languages
English (en)
Inventor
Toshiaki Tagawa
A D Miller
E Perouzel
Karl Murray
Michelle Manvell
Eric Alton
David Matthews
Willie Russell
Original Assignee
Mitsubishi Chem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp
Application granted granted Critical
Publication of ATE318322T1 publication Critical patent/ATE318322T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00981481T 1999-12-23 2000-12-12 Virale kernproteine-kationische lipid- nukleinsäure-verabreichungkomplexe ATE318322T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930533.6A GB9930533D0 (en) 1999-12-23 1999-12-23 Nucleic acid delivery

Publications (1)

Publication Number Publication Date
ATE318322T1 true ATE318322T1 (de) 2006-03-15

Family

ID=10866964

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00981481T ATE318322T1 (de) 1999-12-23 2000-12-12 Virale kernproteine-kationische lipid- nukleinsäure-verabreichungkomplexe

Country Status (16)

Country Link
US (2) US20030153081A1 (de)
EP (2) EP1566445A3 (de)
JP (1) JP2003518388A (de)
CN (1) CN100354426C (de)
AT (1) ATE318322T1 (de)
AU (1) AU781356B2 (de)
CA (1) CA2395454A1 (de)
CZ (1) CZ298353B6 (de)
DE (1) DE60026164T2 (de)
DK (1) DK1244805T3 (de)
ES (1) ES2258986T3 (de)
GB (1) GB9930533D0 (de)
PT (1) PT1244805E (de)
RU (1) RU2267536C2 (de)
UA (1) UA77393C2 (de)
WO (1) WO2001048233A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0118517D0 (en) * 2001-07-30 2001-09-19 Mitsubishi Tokyo Pharm Inc Compound
FR2829136B1 (fr) * 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
JP4629333B2 (ja) * 2001-08-29 2011-02-09 アベンティス・ファーマ・ソシエテ・アノニム アミノグリコシドの脂質誘導体
JP2006527763A (ja) 2003-06-18 2006-12-07 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム スフィンゴ脂質のポリアルキルアミン抱合体
US7906122B2 (en) 2003-06-18 2011-03-15 Yissum Research Development Company Of The Hebrew University Of Jersusalem Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
GB0418172D0 (en) * 2004-08-13 2004-09-15 Ic Vec Ltd Vector
WO2007061762A2 (en) * 2005-11-18 2007-05-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt And Human Services Non-viral gene delivery complex
US20110002851A1 (en) * 2006-11-03 2011-01-06 Medigene Ag Cationic Colloidal Carriers for Delivery of Active Agents to the Blood-Brain Barrier in the Course of Neuroinflammatory Diseases
JPWO2008056623A1 (ja) * 2006-11-09 2010-02-25 第一三共株式会社 核酸導入用組成物
EP2105145A1 (de) 2008-03-27 2009-09-30 ETH Zürich Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
WO2010042751A2 (en) * 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
EP3699172A3 (de) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
CA2847888A1 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
DE21212055T1 (de) 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016176330A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
US10829787B2 (en) * 2015-10-14 2020-11-10 Life Technologies Corporation Ribonucleoprotein transfection agents
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20190336611A1 (en) * 2016-06-09 2019-11-07 Curevac Ag Hybrid carriers for nucleic acid cargo
WO2017212009A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
JP7179715B2 (ja) * 2016-07-27 2022-11-29 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 核酸送達用の崩壊性細胞透過性複合体
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
EP3568155A4 (de) 2017-01-11 2020-09-23 The Trustees Of The University Of Pennsylvania Nukleosid-modifizierte rna zur induktion einer immunreaktion gegen zika-virus
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
US11596679B2 (en) 2017-04-27 2023-03-07 Vanderbilt University Hepatitis C virus gene sequences and methods of use therefor
US11820728B2 (en) 2017-04-28 2023-11-21 Acuitas Therapeutics, Inc. Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP7355731B2 (ja) 2017-08-16 2023-10-03 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
JP7461872B2 (ja) 2017-08-17 2024-04-04 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP3852911B1 (de) 2018-09-21 2025-01-22 Acuitas Therapeutics, Inc. Systeme und verfahren zur herstellung von lipidnanopartikeln und liposomen
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
PL3908568T3 (pl) 2019-01-11 2024-12-02 Acuitas Therapeutics, Inc. Lipidy do dostarczania środków czynnych w nanocząstkach lipidowych
JP7630904B2 (ja) * 2019-07-23 2025-02-18 株式会社東芝 核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法
CN110408656A (zh) * 2019-07-29 2019-11-05 成都朴名生物科技有限公司 脂多聚物体及其制备方法、采用脂多聚物体将基因编辑质粒导入真核细胞的方法
CN110452303B (zh) * 2019-08-08 2022-03-04 中国科学院武汉病毒研究所 共价连接核酸和肽或蛋白的方法及应用
CA3178344A1 (en) 2020-03-31 2021-10-07 The Trustees Of The University Of Pennsylvania Universal influenza vaccine using nucleoside-modified mrna
CN111394313A (zh) * 2020-04-01 2020-07-10 河南科技学院 一种人造细胞及其制备方法
EP4178544A4 (de) 2020-07-08 2024-09-25 The Trustees of the University of Pennsylvania Nukleosidmodifizierte rna zur induktion einer immunreaktion gegen sars-cov-2
KR20230051172A (ko) 2020-07-16 2023-04-17 아퀴타스 테라퓨틱스 인크. 지질 나노 입자에 사용하기 위한 양이온성 지질
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CN114656422B (zh) * 2022-04-22 2023-05-23 重庆理工大学 一种新型氮杂冠醚化合物及其阳离子脂质体、制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1322987A (en) * 1969-12-29 1973-07-11 Richter Gedeon Vegyeszet On,n-diacylhydroxylamine derivatives and preparation
US4189431A (en) * 1975-08-04 1980-02-19 The Board of Trustees of Leland Stanford Junior University Alkinyl terminating groups in biogenetic-like cyclizations to steroids
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US5510510A (en) * 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
WO1996040961A1 (en) * 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
CN1181422A (zh) * 1996-10-31 1998-05-13 上海市肿瘤研究所 与生长因子受体结合的多肽所构建的基因转移载体
DK1163258T3 (da) * 1999-03-09 2003-03-31 Akzo Nobel Nv Derivater af 22R-hydroxycholesta-8, 14-dien til inhiberingen af meiosis

Also Published As

Publication number Publication date
US20090209037A1 (en) 2009-08-20
CA2395454A1 (en) 2001-07-05
DE60026164T2 (de) 2006-11-16
RU2267536C2 (ru) 2006-01-10
EP1566445A2 (de) 2005-08-24
EP1244805A1 (de) 2002-10-02
ES2258986T3 (es) 2006-09-16
CN100354426C (zh) 2007-12-12
DE60026164D1 (de) 2006-04-27
AU781356B2 (en) 2005-05-19
JP2003518388A (ja) 2003-06-10
EP1244805B1 (de) 2006-02-22
UA77393C2 (en) 2006-12-15
EP1566445A3 (de) 2005-08-31
DK1244805T3 (da) 2006-06-26
RU2002119560A (ru) 2004-03-27
CZ298353B6 (cs) 2007-09-05
GB9930533D0 (en) 2000-02-16
AU1871601A (en) 2001-07-09
US20030153081A1 (en) 2003-08-14
PT1244805E (pt) 2006-07-31
CZ20022193A3 (cs) 2003-02-12
CN1434870A (zh) 2003-08-06
WO2001048233A1 (en) 2001-07-05

Similar Documents

Publication Publication Date Title
DE60026164D1 (de) Virale kernproteine-kationische lipid-nukleinsäure-verabreichungkomplexe
WO2000073316A3 (en) Virus immunologic determinants
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
FI941473A0 (fi) Uusia konjugaatteja nukleiinihappojen viemiseksi korkeampiin eukaryoottisiin soluihin
CA2305013A1 (en) Fusion proteins comprising hiv-1 tat and/or nef proteins
CA2020668A1 (en) Fused or hybrid protein comprising viral antigen and lymphokine
NO20002800L (no) Cyklosporinholdig mikroemulsjon, for konsentratsammensetning
AU3192889A (en) T cell activation markers
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
FR2799758B1 (fr) Complexe a base d'acide orthosilicique biologiquement assimilable, se presentant sous forme solide, stable et concentree, et procede de preparation
WO1997031934A3 (de) Neue metabolisierbare lipopolyamine, deren darstellung und anwendung
WO1999067382A3 (en) Angiopoietin-like growth factor sequences
AU630861B2 (en) Recombinant hiv-2 polypeptides
WO1997040147A8 (en) Antigenically reactive regions of the hepatitis a virus polyprotein
WO2000063385A3 (en) Nucleic acid immunization
PT1165797E (pt) Partículas para a terapia genética
DK0442372T3 (da) Forbedrede mærkede haptener, fremgangsmåde til deres fremstilling samt anvendelse af disse mærkede haptener ved immunoassays
WO2000061747A3 (en) Clasp-2 transmembrane proteins
AU3282900A (en) Target cell-specific, multivalent proteins (mvp)
DE60026666D1 (de) Induktion von antigen-spezifischen T-Zellen durch Interferon
WO2003093440A3 (en) Methods and compositions for expressing a nucleic acid in a dendritic cell
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
CY1105693T1 (el) Συμπλοκα μεταφορας πρωτεϊνης ιικου πυρηνα-κατιοντικου λιπιδιου-νουκλεϊνικου οξεος
WO2001042297A3 (en) Clasp-3 transmembrane protein
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1244805

Country of ref document: EP

REN Ceased due to non-payment of the annual fee